GT BIOPHARMA, INC. Unrealized Gain (Loss) on Derivatives
GT BIOPHARMA, INC. (GTBP) reported Unrealized Gain (Loss) on Derivatives of -$502.00 thousand for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-10.
Discontinued › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnDerivatives · last filed 2021-11-10
- GT BIOPHARMA, INC. unrealized gain (loss) on derivatives for the quarter ending 2021-09-30 was -$502.00K.
- GT BIOPHARMA, INC. unrealized gain (loss) on derivatives for the quarter ending 2020-09-30 was $0.00.
| Period end | Unrealized Gain (Loss) on Derivatives 3 month | Unrealized Gain (Loss) on Derivatives 9 month |
|---|---|---|
| 2021-09-30 | -$502.00K 10-Q · filed 2021-11-10 | -$43.00K 10-Q · filed 2021-11-10 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |